NASDAQ$TSHA
Taysha Gene Therapies Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Taysha Gene Therapies reported financial results for the third quarter of 2021 and provided a corporate update.
Taysha Gene Therapies reported a net loss of $51.2 million for Q3 2021. The company made significant advances across multiple programs, including regulatory meetings and preclinical data publications.
- Submitted an end-of-Phase meeting request for TSHA-120 with a major ex-US regulatory agency.
- Expect to report clinical safety and functional MFM32 data for TSHA-120 from the high dose cohort in December.
- Remain on track to report preliminary clinical safety data and Hex A enzyme activity for TSHA-101 in December.
- Anticipate preliminary clinical data for the first-generation construct in CLN7 disease in December.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Taysha Gene Therapies anticipates several milestones across its programs and expects to provide updates throughout the remainder of the year.
Tailwinds
- Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort in GAN in December 2021.
- Expect preliminary clinical safety data and Hex A enzyme activity for TSHA-101 in GM2 gangliosidosis in December 2021.
- Anticipate preliminary clinical data for the first-generation construct in CLN7 disease in December 2021.
- On track to initiate Phase 1/2 trials for TSHA-118 in CLN1 disease and TSHA-102 in Rett syndrome by year-end 2021.
- Expect to finalize the second-generation CLN7 construct by year-end and initiate a planned pivotal clinical trial in 2022 with reference to clinical data from the first-generation construct.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro